Hot Flash Remedy report
Serum estradiol remains higher with this therapy (around 50 pg ml), so side effects related to low estrogen are less prevalent. In one study, endometriosis patients undergoing this treatment reported a symptom-free period, with no mood changes, hot flushes, libido loss, vaginal dryness, or other symptoms.
The Chronic Radiation Syndrome (CRS) was defined as a complex clinical syndrome occurring as a result of the long-term exposure to total radiation doses that regularly exceed the permissible occupational dose by far (2-4 Sv year). Clinical symptoms are diffuse and may include sleep and or appetite disturbances, generalized weakness and easy fatigability, increased excitability, loss of concentration, impaired memory, mood changes, headaches, bone pain, and hot flashes. The severity of delayed effects depends on dose. These delayed effects may include cancer, cataracts, non-malignant skin damage, death of non-regenerative cells tissue, genetic damage, impact on fertility, and suppression of immune functions.
Hormone ablation is typically used to treat (i) prostate cancer, via either orchiectomy or androgen antagonists, and (ii) hormone receptor-positive breast cancer, with estrogen antagonists. There is a burgeoning literature on the effects of sex hormones on cognitive functioning. Serum testosterone may be related to spatial ability. Women on gonadotropin-releasing hormone agonists for gynecological problems, which inhibit both testosterone and estrogen release, have reported declines in their memory functioning and mood. These deficits appear to be reversed with estrogen replacement. Tamoxifen is the most widely used hormonal agent in the treatment of breast cancer. The most commonly reported adverse effects associated with Tamoxifen include hot flashes, nausea, and vaginal bleeding. Additionally, fatigue and inability to concentrate have been reported as well as mood changes, including depression, irritability, and nervousness. Although the pharmacodynamic properties of Tamoxifen,...
A discrete period of intense fear or discomfort, in which at least four (or more) of the following symptoms developed abruptly and reached a peak within 10 minutes palpitations, pounding heart, or accelerated heart rate sweating trembling or shaking sensations of shortness of breath or smothering feeling of choking chest pain or discomfort nausea or abdominal distress feeling dizzy, unsteady, lightheaded, or faint derealization (feeling of unreality) or depersonal-ization (being detached from oneself) fear of dying pares-thesias (numbness or tingling sensations) and chills or hot flashes. Limited-symptom attacks require the same criteria, except that fewer than four symptoms of panic are required.
The most common symptom of menopause is the hot flash, which occurs in 75 percent of women. Flashes are self-limited, with 50 to 75 percent of women having cessation of hot flashes within five years. B. Hot flashes typically begin as the sudden sensation of heat centered on the face and upper chest, which rapidly becomes generalized. The sensation of heat lasts from two to four minutes, is often associated with profuse perspiration and occasionally palpitations, and is often followed by chills and shivering. Hot flashes usually occur several times per day.
The structure of soybean isoflavonoids is uniquely similar to that of estrogen (17) and may account for their weak ability to act as agonists at estrogen receptors (38). Many have speculated that soybean isoflavonoids may be useful for the treatment of somatic, mood, and cognitive disturbances associated with the onset of menopause (39). Diet supplementation with soybean phytoestrogens has been reported to ameliorate hot flashes and other symptoms of menopause (40-43).
Perimenopause is defined as the two to eight years preceding menopause and the one year after the last menstrual period. It is characterized by a normal ovulatory cycle interspersed with anovulatory cycles. Menses become irregular, and heavy breakthrough bleeding can occur. Some women complain of hot flashes and vaginal dryness.
Several preparations containing only 20 g of ethinyl estradiol are now available (Lo-Estrin 1 20, Mircette, Alesse, Aviane). These are often used for perimenopausal women who want contraception with the lowest estrogen dose possible. These preparations provide enough estrogen to relieve vasomotor flashes. Perimenopausal women often experience hot flashes and premenstrual mood disturbances during the seven-day pillfree interval. Mircette, contains 10 g of ethinyl estradiol on five of the seven placebo days, which reduces flashes and mood symptoms.
Of concern have been the possible side effects of long-term tamoxifen use, in particular the risk of endometrial cancer. However, this must be balanced against the protective effect of tamoxifen in post-menopausal women in reducing cardiovascular-associated disorders (e.g. strokes). In addition, tamoxifen may reduce the risks of the development of a contralateral breast cancer by up to 30 although this benefit is less pronounced with time. Other side effects of tamoxifen include vaginal dryness, loss of libido and hot flushes. Weight gain is often attributed to tamoxifen but in placebo-controlled trials this did not appear to be confirmed. A small number of patients may develop retinal damage.
The existence of subgroups of PMS of varying etiology may account for clinical observations that some women with severe premenstrual depression report, paradoxically, a worsening of symptoms during progesterone treatment. Indeed, such women have been reported to respond to oestrogen treatment. Their condition may be linked to progesterone excess, which has been suggested to occur in some women who experience PMS symptoms at midcycle. High luteal progesterone levels may lead to depletion of oestrogen receptors of the hypothalamus, which is consequently less sensitive to oestrogen, requiring a higher midcycle oestrogen surge for normal pituitary response. This is followed by an abrupt and pronounced oestrogen drop at midcycle which may even result in symptoms of hot flushes.
Various writers have noted that for women, the fourth and fifth decades of life, in its association with menopause, often provide a key turning point in both the biological and social worlds of females and may mark the beginning of a label of old. Cross-cultural work in this area has shown the need for sophisticated research that takes a bio-cultural approach to this issue (du Toit, 1990 Flint & Samil, 1990 Kaufert & Lock, 1992 Lock, 1993). The complex interplay of biology, nutrition, and culture in shaping women's experience of menopause is analyzed by Yewoubdar Beyene's in From Menarche to Menopause Reproductive Lives of Peasant Women in Two Cultures (1989). She compares Mayan and Greek women living in rural villages and finds that their experience of menopause and aging strongly differed, despite similar values and behaviors regarding menstruation and childbearing. Greek women had a substantial, well-balanced diet, married late, and averaged only two pregnancies. Here, menopause...